|
| |
BioJournal -
Arrowhead Publications
To view descriptions and
buy online -
click
here! or select the title!
 |
The global anti-infective market is currently valued at US$66.5 billion
with antibacterial agents accounting for over 50% of sales. The
antibacterial market is set to grow to over US$45.0 billion by 2012, driven
by the uptake of newer antibacterial agents such as glycopeptides and
carbapenems which demonstrate resistance to methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as
well as other emerging strains. |
|
|
The global anti-infective market is currently valued at US$66.5
billion with antiviral agents accounting for 24% of sales (excluding
vaccines which target viral infectious diseases).
According to Arrowhead Publishers’ new report The Antivirals Market:
R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral
market is set to grow to over US$25.0 billion by 2012 driven by the
uptake of newer anti-retroviral agents in combination therapy and the
launch of ten new products for the treatment of HIV and hepatitis which
will address the need of treatment-resistant patients. This will help to
stem the tide of this prevalent and often lethal killer in our society
today. |
|
|
|
Offshoring clinical trials to emerging markets around the world is
receiving increasing attention as a very attractive alternative in the
clinical development process. This follows as a natural reaction to
already successful offshoring activities in the IT industry. The big
question is: Do clinical research capabilities comparable to the US in
terms of sophistication and FDA-compliance exist anywhere else in the
world? And if they do, are they ready to handle the huge surge in
business likely headed their way? |
|
|
|
The clinical trials industry has clear potential for strong growth
in the future, driven by technological and scientific advances. This
trend is complemented by the development of new trial designs, with a
view to rationalizing and accelerating the drug discovery process by
identifying failures at an earlier stage. |
|
|
|
With a market size of US$14.5 billion in 2005 and an anticipated
value of US$16.5 billion in 2006, the neurodegenerative market
represents a valuable, fast-growing opportunity in the pharma/biotech
industry. An increase in the number of aged people, increased life
expectancy, unmet clinical needs together with advances in treatments of
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease
will continue to contribute to the expansion of the global market. |
|
|
|
In 2005, the antibodies market was valued at an estimated US$14
billion, accounting for over 24 percent of the total protein
therapeutics market. This share increased substantially since 2001, when
it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies
have been posting the fastest growth within the protein therapeutics
market. According to Arrowhead Publishers’ report Monoclonal Antibody
Therapies 2007: Competitive Landscape and Pipeline Insight the value of
this market is set to reach more than $16 billion in 2006This growth
will continue in the coming years, boosted by a number of new MAbs on
the market, new indications for successful medications, and their
ability to treat conditions and diseases for which there is great unmet
need. |
|
|
|
The global protein therapeutics market was valued at US$57 billion
in 2005. Biotechnology has made notable inroads in the field of protein
therapeutics, resulting in some of the key products presently available
in the category. Recombinant proteins are potentially advantageous in
terms of higher efficacy and fewer side effects than other
pharmaceutical products, as they can be more specifically targeted to
the cause of the disease, rather than the treatment of its symptoms. |
|
 |
As competition in the pharmaceutical marketplace grows, companies
are increasingly looking towards the drug delivery industry to maximize
revenues and combat generic competitors. The search for more efficient
drug delivery systems is also being driven by the rise in patient
demand, healthcare and pharma cost containment, as much as by medical
and technological advances. |
|
|
|
The market for rheumatoid arthritis therapeutics has experienced
remarkably strong growth during the past five years due to the
introduction of the biological response modifiers (BRMs) to treatment
regimens. The value of this market will reach nearly $13 billion by
2011. Sales of both Remicade and Enbrel continue to grow, while the
introduction of Humira in 2003 has been a major stimulus to the market.
All three of these products are now approved in both the US and Europe
for rheumatoid arthritis. Added to this mix in 2006 was Rituxan and
Orencia, which will both have an impact in the patient population
unresponsive to other BRMs. As half-year 2006 revenues clearly indicate,
revenues from the sales of all of these products will continue to trend
positively in 2007. |
|
|
|
Since the mid-1990s, pharma companies have devised their sales and
marketing strategies based on Rx data.
However, with the introduction of the AMA's Prescribing Data Restriction
Program (PDRP) opt-out program in July 2006, pharma companies need to
evaluate the impact of PDRP violation, mediate their PDRP compliance
strategies, and revisit their existing Sales Force Effectiveness (SFE)
practices. With the introduction of the PDRP, the use of physician Rx
data by pharmaceutical companies will never be the same again. The PDRP
prohibits access to physician-level Rx data, which directly impacts
First Line Managers, Sales Representatives, and anyone else that
accesses or distributes physician Rx data. |
|
|
|
Diabetes is one of the largest therapeutic segments of global
pharmaceutical sales and during the last 10 years it has grown by a
compound average growth rate of nearly 20% from around US$4 billion in
1995 to over US$17 billion in 2005. Overall, anti-diabetic drugs sales
are expected to grow dramatically over the next five years to over US$22
billion in 2012 as the addressable patient population continues to
increase and new, oral, injectable and pulmonary premium priced products
enter the market to address high unmet clinical needs.
The Global Diabetes Market assesses the markets for diabetes
therapeutics, as well as the markets for diagnostic products and those
that treat diabetic complications. |
|
|
|
The drug delivery industry has in recent years become a key partner
for pharmaceutical companies in their efforts to maximize the patent
lives of successful products. Drug delivery companies not only stand to
benefit from patent expiry by providing their reformulation services to
pharmaceutical companies, but also by producing their own versions of
branded products with improved delivery mechanisms. Thus, post-patent
expiry sales can be switched from the ethical manufacturer to the drug
delivery sector. |
|
|
|
Despite their diversity, global healthcare systems are increasingly
converging in the need and desire to contain costs of healthcare, and
especially those associated with pharmaceuticals. At the same time, Big
Pharma are having to contend with a dearth of invention, patent
expirations, and increased generic competition, among other factors
undermining their profits. In this environment, the importance of market
access strategies, especially in terms of pricing, reimbursement and
parallel trade are rapidly gaining prominence. |
|
|
|
Together, the four major cancer markets, which include colorectal,
prostate, lung and breast cancer were valued at well over $16 billion in
2005, which was an increase of 14 percent in value since 2004. Driving
this growth are innovative new products, line extensions for existing
products, and the coming of age of the biotech industry. |
|
|
|
An Examination of Commercial and Regulatory Contrasts.
The US generics market was estimated at US$18.1 billion in 2004; the
leading European generics markets together totalled between US$10–US$11
billion for the same period. This new report asks why there is such a
difference in value? |
|
|
|
Amgen is the world’s largest biotechnology company and the eighth
largest pharmaceutical company worldwide. Revenues have nearly doubled
in the last three years, going from $5.52 billion in 2002 to $10.55
billion in 2004. Yet the majority of revenue is based on twenty-year old
technology. Can Amgen continue its amazing revenue growth? Or will it
fall behind, lacking the small molecule therapeutics that are the
mainstay of modern pharmaceuticals? |
|
|
|
Pain Therapeutics 2005: Market Dynamics and Outlook provides
detailed analysis and information concerning the global market for pain
therapeutics, R&D pipelines and company involvement in this field.
About one and a half billion people suffer from moderate to severe
chronic pain worldwide and approximately 50 million Americans suffer
with pain. The value of the pharmaceutical market for pain relief
reflects this seeming worldwide epidemic of pain, with the overall value
reaching nearly $23 billion in 2004. |
|
|
|
This new 213-page report has been written to provide members of
pharmaceutical, biotechnology and clinical research sectors an
analytically-based overview of the mechanisms of the partnering process,
and the key issues and trends affecting these arrangements.
Alliances and external collaborations have provided companies with the
opportunity to gain access to new technological breakthroughs and novel
expertise regardless of national or geographical boundaries. Evidence of
the growing emphasis on alliances and external collaborations as a route
to success is highlighted by the fact that partnerships within the
biopharmaceutical sector are currently being formed at the rate of $5
billion per year. |
|
|
|
The value of biological drugs indicated for autoimmune diseases,
which affect up to 5% of the total world
population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira
and Avonex currently lead the autoimmune field. These drugs are
transforming the treatment of autoimmune diseases. In addition, novel
therapies for psoriasis, asthma, and lupus will in the near future add
tremendous revenue to an already rapidly growing field. |
|
| |
|
